Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBPY), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TC BioPharm (Holdings)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TC BioPharm (Holdings)'s position in the market.
TC BioPharm (OTC: TCBPY) has secured a significant patent from the European Patent Office for its modified gamma delta T cell therapies targeting microbial, oncological, and viral indications. The patent strengthens the company's intellectual property portfolio in the development of allogeneic cell therapies.
According to CEO Bryan Kobel, this patent advancement is particularly important as it addresses the challenge of off-target recognition in modified cell therapies, potentially enabling broader therapeutic applications while reducing toxicity risks. The company plans to proceed with the patent process in specific European countries in line with its commercial strategy.
FAQ
What is the current stock price of TC BioPharm (Holdings) (TCBPY)?
